Pharma Industry Under Antitrust Scrutiny

Law360, New York (January 13, 2010, 10:57 AM EST) -- Competition authorities continue to examine various aspects of the pharmaceutical industry. Most recently, the European Commission conducted surprise inspections of certain pharmaceutical companies, seeking evidence of anti-competitive conduct.

One issue of concern is the impact on competition of "pay-for-delay" or "reverse payment" patent settlement agreements, whereby branded pharmaceutical manufacturers make payments to generic manufacturers in exchange for delaying their entry.

Although this issue has yet to be a specific focus of concern in Canada, recent amendments to the Competition Act (to come into force in March...
To view the full article, register now.